SABCS 2017

Area: Oncology

Location: San Antonio, United States

Date: December 5 to December 9

Description:

San Antonio Breast Cancer Symposium.


Search in Scientific Content:
Date
Filters:
Increasing
11:01

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis

Presenter: Richard Gray
Oncology : Breast Cancer
Phase Ib/I
8:36

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)

Presenter: Sherene Loi
Oncology : Breast Cancer
Randomized
7:31

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women whith Early Stage Breast Cancer (SWOG 1200)

Presenter: Dawn L. Hershman
Oncology : Breast Cancer
A prospect
8:35

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

Presenter: Michael Gnant
Oncology : Breast Cancer
NSABP B-47
7:37

NSABP B-47 (NRG Oncology) Phase III RCT Comparing Adjuvant Chemotherapy AC-Weekly Paclitaxel (WP) or TC x 6 with or without Trastuzumab for 1 Year in High-risk, Invasive Breast Cancer, Negative for HER2 by ISH and with IHC 1+ or 2+ (HER2-Low IBC)

Presenter: Louis Fehrenbacher
Oncology : Breast Cancer
Pooled ana
8:23

Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in prmenopausal early breast cancer patients

Presenter: Matteo Lambertini
Oncology : Breast Cancer
A randomiz
9:05

A randomized phase III study pf adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer

Presenter: Heikki Joensuu
Oncology : Breast Cancer
Targeted t
4:18

Targeted therapy, HER2 positive news

Presenter: Mothaffar Rimawi
Oncology : Breast Cancer
Management
6:50

Management Controversies in Locoregional Recurrence - Symposium Summary

Presenter: Irene Wapnir
Oncology : Breast Cancer
Exosome an
7:53

Exosome analysis in breast cancer: Clinical translation

Presenter: Jacqueline F. Bromberg
Oncology : Breast Cancer
HER2+
5:59

HER2+

Presenter: Louis Fehrenbacher
Oncology : Breast Cancer
Challanges
2:27

Challanges in the management of locoregional recurrence

Presenter: Monica Morrow
Oncology : Breast Cancer
Results of
4:41

Results of SOLD Study

Presenter: Heikki Joensuu
Oncology : Breast Cancer
Highlights
7:19

Highlights of the congress

Presenter: Matteo Lambertini
Oncology : Breast Cancer

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States

ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria

ESMO 2017

2017-09-08 - 2017-09-12
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark

ASCO 2016

2016-06-03 - 2016-06-07
Chicago, United States